By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Reata Pharmaceuticals, Inc. 

1950 Stemmons Freeway, Suite 5001

Dallas  Texas  75207  U.S.A.
Phone: 214-800-8700 Fax: 214-722-0867



Company News
Abbott Laboratories (ABT), Reata Pharmaceuticals, Inc. Kidney Disease Drug Trial Stopped 10/18/2012 9:42:10 AM
Reata Pharmaceuticals, Inc. to Present at 30th Annual J.P. Morgan Healthcare Conference 1/6/2012 11:13:10 AM
Reata Pharmaceuticals, Inc. Release: New Study Points to Novel Mechanism by Which Tumors Escape Recognition by the Immune System 11/29/2011 11:52:45 AM
Reata Pharmaceuticals, Inc. Adds Executives to Management Team and Board of Directors 10/17/2011 10:46:12 AM
Reata Pharmaceuticals, Inc. and Abbott Laboratories (ABT) Initiate Global Phase 3 Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes 6/16/2011 9:08:28 AM
Reata Pharmaceuticals, Inc. and Abbott Laboratories (ABT) Announce Positive Phase 2b Study Results for Bardoxolone Methyl 11/22/2010 7:51:39 AM
Reata Pharmaceuticals, Inc. to Present Data from Pivotal Phase 2b Trial in Type 2 Diabetics With Chronic Kidney Disease 11/11/2010 11:27:26 AM
Reata Pharmaceuticals, Inc. Adding Jobs, Stays in Dallas Because of Abbott Laboratories (ABT) Deal 10/4/2010 8:25:58 AM
Abbott Laboratories (ABT) and Reata Pharmaceuticals, Inc. Announce Agreement Worth at Least $450 Million to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S. 9/23/2010 6:42:11 AM
Reata Pharmaceuticals, Inc. Completes $78 Million Equity Financing for Second Pivotal Trial of Bardoxolone Methylr 7/12/2010 7:14:53 AM